Propanc Biopharma (NASDAQ:PPCB) Trading Down 5.5% – What’s Next?

Propanc Biopharma Inc (NASDAQ:PPCB) traded down 5.5% during trading on Monday . The stock traded as low as $1.31 and last traded at $1.37. 28,973 shares changed hands during mid-day trading, a decline of 55% from the average session volume of 64,605 shares. The stock had previously closed at $1.45.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised Propanc Biopharma from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Propanc Biopharma presently has an average rating of “Sell”.

Propanc Biopharma Price Performance

The stock has a market cap of $3.08 million, a price-to-earnings ratio of -0.06 and a beta of 3.48. The stock’s 50 day simple moving average is $2.30 and its two-hundred day simple moving average is $7.50.

Institutional Investors Weigh In On Propanc Biopharma

An institutional investor recently bought a new position in Propanc Biopharma stock. Virtu Financial LLC purchased a new stake in shares of Propanc Biopharma Inc (NASDAQ:PPCB) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 41,677 shares of the company’s stock, valued at approximately $71,000. Virtu Financial LLC owned about 0.33% of Propanc Biopharma as of its most recent SEC filing.

About Propanc Biopharma

Propanc Biopharma Ltd is a clinical-stage biotechnology company focused on developing novel biologic drug candidates for the treatment of invasive and metastatic cancers. The company’s core technology centers on proprietary formulations of recombinant human proteolytic enzymes designed to degrade the dense extracellular matrix that surrounds solid tumors. By reducing stromal barriers, these candidates are intended to enhance the delivery and efficacy of co-administered chemotherapies, immunotherapies or other targeted agents.

The company’s lead program, known as PRP, comprises a combination of modified pancreatic proteases that have demonstrated promising preclinical activity in degrading tumor stroma and inhibiting tumor growth.